

## A Stereoselective Synthesis of C26-C36 Fragment of Arenicolide A


Jung Lyul Lee, Seo-Jung Han, and Duck-Hyung Lee\*

Department of Chemistry, Sogang University, Seoul 121-742, Korea. \*E-mail: dhlee@sogang.ac.kr


Received May 7, 2009, Accepted May 21, 2009

**Key Words:** Arenicolide A, Anti-cancer activity, Stereoselective synthesis, Brown allylation, A<sup>1,3</sup>-strain

Recently, arenicolides A (**1**) and B (**2**) were isolated from the large-scale fermentation of the *S. arenicola* strain CNR-005 and its relative stereochemical relationship except C-12, C-30, and C-31 chiral centers was proposed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, Mass, IR, UV, CD, chemical degradation methods.<sup>1</sup> Arenicolides A (**1**) and B (**2**) are 26-membered macrolides with three conjugated dienes and nine chiral centers in the ring. There is one side chain which comprises the C-26 ~ C-36 carbon chain with five consecutive chiral centers. Arenicolide A (**1**) also showed moderate anti-cancer activity toward the human colon adenocarcinoma cell line HCT-116 (IC<sub>50</sub>; 30 µg/mL) and three cell lines in the National Cancer Institute, and no activity against antimicrobial assay using methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *E. faecium* (VREF).<sup>1</sup>




Arenicolide C (**3**) was also isolated along with arenicolides A (**1**) and B (**2**). And we proposed that the cyclic ether moiety in **3** might be derived biologically from arenicolide A (**1**) via the acid-catalyzed opening of epoxide and S<sub>N</sub>2 type addition of the C-33 hydroxyl group. In this paper, we report the stereoselective synthesis of the plausible C-26 ~ C-36 side chain (**10**) of arenicolide A (**1**) based on this assumption.




Retrosynthesis is summarized in Scheme 1. The homoallyl chiral center at C-31 of **4** would be introduced by asymmetric allylation of aldehyde.<sup>2</sup> Conformational control from the

allylic 1,3-strain and approach of the epoxidizing reagent *anti* to the methoxy group in **5** should provide the desired stereochemistry of C-30 and C-31 epoxide in **4**.<sup>3</sup> Finally, diastereoselective 1,2-*syn* aldol strategy of α-methoxyacetate moiety **6** would be used to construct the C-32 and C-33 chiral centers.<sup>4</sup>

The synthesis of target molecule **10** was summarized in Scheme 2. Evans-*syn* aldol reaction of α-methoxyacetate **6** with *n*-butanol provided the 1,2-*syn* aldol product in 96% yield,<sup>4</sup> and the free β-hydroxyl group was treated by TBSOTf and 2,6-lutidine to afford the TBS-ether **7** in 84% yield. The chiral auxiliary group of **7** was removed by reduction with LiBH<sub>4</sub> in 94% yield,<sup>5</sup> the resulting hydroxyl group was oxidized by Swern oxidation in 91% yield, and the resulting aldehyde was treated with stabilized Wittig reagent to afford the α,β-unsaturated ester **8** in 92% yield. The ester group of **8** was reduced to primary alcohol by DIBAL in methylene chloride in 94% yield and the diastereoselective epoxidation by *m*CPBA provided the desired epoxide **9** and its isomer in 72%.<sup>3</sup> Swern




Scheme 1. Retrosynthesis



**Scheme 2.** Synthesis of C26-C36 Fragment (**4**). (a) *n*-Bu<sub>2</sub>BOTf (1.5 eq), Et<sub>3</sub>N (1.6 eq), butyraldehyde (2.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 4 hr, 96%. (b) TBSOTf (1.2 eq), 2,6-lutidine (2.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 3 hr, 84%. (c) LiBH<sub>4</sub> (1.12 eq), water (1.12 eq), ether, rt, 45 min, 94%. (d) (COCl)<sub>2</sub> (2.5 eq), DMSO (4.5 eq), Et<sub>3</sub>N (7.5 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 1.5 hr, 91%. (e) Ph<sub>3</sub>P=C(Me)CO<sub>2</sub>Et (2.5 eq), benzene, reflux, overnight, 92%. (f) DIBAL (5.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 2 hr, 94%. (g) *m*CPBA (1.5 eq), K<sub>2</sub>HPO<sub>4</sub> (3.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, rt, 18 hr, 72%. (h) (COCl)<sub>2</sub> (2.0 eq), DMSO (4.0 eq), Et<sub>3</sub>N (5.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 40 min, 88%. (i) (-)-Ipc<sub>2</sub>BOMe (1.2 eq), allylmagnesium bromide (2.0 eq), ether, -100 °C, 3 hr, 67%. (j) TBSOTf (1.5 eq), 2,6-lutidine (2.0 eq), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 30 min, 88%.

oxidation of primary alcohol **9** (88%) and chiral-ligand assisted asymmetric allylation of the resulting aldehyde (67%)<sup>2</sup> produced the homoallylic alcohol with the correct stereochemistry at C-29 in 67% yield along with its isomer in 19% yield. Finally, protection of the secondary alcohol with TBSOTf and 2,6-lutidine completed the synthesis of plausible C-26 ~ C-36 side chain moiety (**10**) of arenicolide A (**1**).


The origin of diastereoselectivity in the epoxidation reaction can be rationalized by conformational preferences of conformation **A** over conformation **B** due to the  $A^{1,3}$ -strain.<sup>6</sup> In addition, hydroxyl-group directed epoxidation<sup>7</sup> and *anti*-periplanar approach of the electrophilic oxygen to the best  $\sigma$ -electron acceptor (methoxy group)<sup>8</sup> clearly lead to the desired stereochemistry in **9** through the assembly **A-1** over the **A-2**.



In order to further confirm the relative stereochemical relationship of epoxide **9**, the primary hydroxyl group of **9** was converted to the benzyl ether by treatment with sodium hydride and benzyl bromide in THF in 91% yield, and the TBS-ether was deprotected by TBAF in THF to give the secondary alcohol **11** in 63% yield. After conversion of the secondary alcohol **11** to carbamate **12** by reaction with dimethylcarbamyl chloride in 87% yield, Intramolecular  $\text{BF}_3$ -assisted epoxide-opening and cyclization were carried out in methylene chloride to afford the cyclic carbonate **13** in 52% yield.<sup>9</sup> NOE experiment of **13** confirmed the relative stereochemistry of **13** and therefore that of **9**, an intermediate in the synthesis of target molecule **10**.<sup>10</sup>

In summary, the plausible C-26 ~ C-36 side chain **10** of arenicolide A (**1**) was prepared concisely and efficiently in 10 steps. The key steps are Evans 1,2-*syn* aldol reaction, diastereoselective epoxidation, and asymmetric allylation of aldehyde.

**Acknowledgments.** This research was assisted financially by Korea Science and Engineering Foundation (KOSEF) (2008-0058780 and 2009-0058780). BK21 graduate fellowship grant to J. L. Lee and S. J. Han is gratefully acknowledged. The instrument facilities of the Organic Chemistry Research Center (OCRC) in Sogang University were also helpful.



**Scheme 3.** Confirmation of relative stereochemistry of epoxide **9**. (a) BnBr (1.10 eq), NaH (1.10 eq), *n*-Bu<sub>4</sub>NI (0.40 eq), THF, rt, 3 hr, 91%. (b) TBAF (2.5 eq), THF, rt, 3.5 hr, 63%. (c) Dimethylcarbamyl chloride (1.5 eq), NaH (1.2 eq), DMAP (0.3 eq), DMF, rt, 8 hr, 87%. (d)  $\text{BF}_3 \cdot \text{OEt}_2$  (1.6 eq),  $\text{CH}_2\text{Cl}_2$ , rt, overnight, 52%.

## References

- (a) Williams, P. G.; Miller, E. D.; Asolkar, R. N.; Jesen, R. R.; Fenical, W. *J. Org. Chem.* **2007**, *72*, 5025-5034.
- Brown, H. C.; Jadhav, P. K. *J. Am. Chem. Soc.* **1983**, *105*, 2092-2093.
- (a) Jung, M. E.; D'Amico, D. C. *J. Am. Chem. Soc.* **1997**, *119*, 12150-12158. (b) Saito, S.; Itoh, H.; Ono, Y.; Nishioka, K.; Moriwake, T. *Tetrahedron: Asymmetry* **1993**, *4*, 5-8.
- Evans, D. A.; Bartroli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127-2129.
- Evans, D. A.; Nagorny, P.; Reynolds, D. J.; McRae, K. J. *Angew. Chem. Int. Ed.* **2007**, *46*, 541-544.
- (a) Rossiter, B. E.; Verhoeven, T. R.; Sharpless, K. B. *Tetrahedron Letter* **1979**, *20*, 4733-4736. (b) Tomioka, H.; Suzuki, T.; Oshima, K.; Nozaki, H. *Tetrahedron Letter* **1982**, *23*, 3387-3390.
- Henbest, H. B.; Wilson, R. A. L. *J. Chem. Soc.* **1957**, 1958-1965.
- (a) Wu, Y. D.; Tucker, J. A.; Houk, K. N. *J. Am. Chem. Soc.* **1991**, *113*, 5018-5027. (b) Paddon-Row, M. N.; Rondan, N. G.; Houk, K. N. *J. Am. Chem. Soc.* **1982**, *104*, 7162-7166.
- (a) Kutsumura, N.; Nishiyama, S. *Tetrahedron Letter* **2005**, *46*, 5707-5709. (b) Bravo, F.; McDonald, F. E.; Neiwert, W. A.; Do, B.; Hardcastle, K. I. *Org. Lett.* **2003**, *5*, 2123-2126.
- (a)  $[\alpha]_D^{25} +11.2$  ( $c = 0.0017$  MeOH);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz)  $\delta$  5.86 ~ 5.81 (m, 1H), 5.10 ~ 5.03 (m, 2H), 3.78 ~ 3.74 (dd, 1H), 3.38 (s, 3H), 3.29 ~ 3.27 (dd, 1H), 2.93 ~ 2.90 (m, 1H), 2.84 ~ 2.82 (d, 1H), 2.45 ~ 2.40 (m, 1H), 2.33 ~ 2.29 (m, 1H), 1.66 ~ 1.64 (m, 2H), 1.50 ~ 1.47 (m, 2H), 1.35 (s, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.087 (s, 3H), 0.079 (s, 3H), 0.059 (s, 3H), 0.035 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz)  $\delta$  135.276, 117.008, 80.291, 76.892, 74.172, 60.052, 58.558, 39.179, 35.752, 26.227, 26.022, 13.352, -4.239, -4.287; IR (neat) 2949, 2930, 2857, 1470, 1378, 1243, 1104, 914, 831, 779, 660  $\text{cm}^{-1}$ ; HRMS (ESI) calculated for  $\text{C}_{25}\text{H}_{52}\text{O}_4\text{Si}_2$   $[\text{M}+\text{Na}]^+$   $m/z$  495.3301, found 495.3305.